← Leaderboards
Yizhou Dong
Icahn School Of Medicine At Mount Sinai
$9,119,472
Attributed
$13,363,519
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,363,519 · 8
By mechanism
R01$5,464,690 · 3
U01$3,997,870 · 2
R35$3,845,289 · 2
F32$55,670 · 1
Top collaborators
- Darrell J Irvine9 shared
- Ron Weiss5 shared
- Brian D Brown1 shared
- Alison M Goate1 shared
- Eric J Nestler1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- James C Iatridis$19,034,759
- Darrell J Irvine$37,519,809
- Amy R. Kontorovich$4,545,755
- Chang Yoon Moon$86,012
- Eric J Nestler$73,310,132
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsFormulationDesignSafetyAnimal ModelMessenger RnaMouse ModelNanoparticleProgramsUntranslated RegionsProteinsCell TypeNovel TherapeuticsLeadProductionLipid NanoparticleEngineeringHemophilia ATranslatingGene ExpressionTreatment EfficacyAnimalsLipids
Grant awards (30)
Development of novel lipid nanoparticles for nucleic acids delivery in the brain$843,806
U01 · FY2025 · EB · contact PI
Therapeutic effects of APOE regulation via LNP-RNA formulations in Alzheimer's disease$835,417
R01 · FY2025 · AG · contact PI
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$729,905
R01 · FY2025 · AI · contact PI
Immunotherapy via engineered therapeutic programs in tumors using RNA$639,680
U01 · FY2025 · CA
Construction of in vivo mRNA delivery systems$464,750
R35 · FY2025 · GM · contact PI
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$751,497
R01 · FY2024 · AI · contact PI
Immunotherapy via engineered therapeutic programs in tumors using RNA$607,159
U01 · FY2024 · CA
Construction of in vivo mRNA delivery systems$464,750
R35 · FY2024 · GM · contact PI
Construction of in vivo mRNA delivery systems$96,459
R35 · FY2024 · GM · contact PI
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$62,718
R01 · FY2024 · AI · contact PI
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$778,064
R01 · FY2023 · AI · contact PI
Immunotherapy via engineered therapeutic programs in tumors using RNA$626,885
U01 · FY2023 · CA
Construction of in vivo mRNA delivery systems$464,750
R35 · FY2023 · GM · contact PI
Immunotherapy via engineered therapeutic programs in tumors using RNA$626,885
U01 · FY2022 · CA
Construction of in vivo mRNA delivery systems$223,497
R35 · FY2022 · GM · contact PI
Construction of in vivo mRNA delivery systems$190,245
R35 · FY2022 · GM · contact PI
Immunotherapy via engineered therapeutic programs in tumors using RNA$653,455
U01 · FY2021 · CA
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$392,900
R01 · FY2021 · HL · contact PI
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$392,751
R01 · FY2020 · HL · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$385,000
R35 · FY2020 · GM · contact PI
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$392,607
R01 · FY2019 · HL · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$385,000
R35 · FY2019 · GM · contact PI
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$357,532
R01 · FY2019 · HL · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$42,840
R35 · FY2019 · GM · contact PI
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$392,468
R01 · FY2018 · HL · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$384,998
R35 · FY2018 · GM · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$385,000
R35 · FY2017 · GM · contact PI
Biodegradable nanoparticles, a genome editing platform to treat hemophilia$378,831
R01 · FY2017 · HL · contact PI
Cell-specific and multifunctional drug formulations for in vivo delivery$358,000
R35 · FY2016 · GM · contact PI
Lipidoid Nanoparticles with Simultaneous Multi-Gene Regulation for Cancer Therapy$55,670
F32 · FY2013 · EB · contact PI